Ascentage Pharma Group International

DB:36X Stock Report

Market Cap: €1.7b

Ascentage Pharma Group International Management

Management criteria checks 3/4

Ascentage Pharma Group International's CEO is Dajun Yang, appointed in Jan 2009, has a tenure of 7.17 years. total yearly compensation is CN¥4.78M, comprised of 94.7% salary and 5.3% bonuses, including company stock and options. directly owns 7.39% of the company’s shares, worth €125.03M. The average tenure of the management team and the board of directors is 6.5 years and 4.7 years respectively.

Key information

Dajun Yang

Chief executive officer

CN¥4.8m

Total compensation

CEO salary percentage94.7%
CEO tenure16yrs
CEO ownership7.4%
Management average tenure6.5yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dajun Yang's remuneration changed compared to Ascentage Pharma Group International's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥360m

Mar 31 2024n/an/a

-CN¥643m

Dec 31 2023CN¥5mCN¥5m

-CN¥926m

Sep 30 2023n/an/a

-CN¥902m

Jun 30 2023n/an/a

-CN¥879m

Mar 31 2023n/an/a

-CN¥881m

Dec 31 2022CN¥4mCN¥4m

-CN¥883m

Sep 30 2022n/an/a

-CN¥848m

Jun 30 2022n/an/a

-CN¥812m

Mar 31 2022n/an/a

-CN¥797m

Dec 31 2021CN¥5mCN¥5m

-CN¥782m

Sep 30 2021n/an/a

-CN¥759m

Jun 30 2021n/an/a

-CN¥735m

Mar 31 2021n/an/a

-CN¥706m

Dec 31 2020CN¥4mCN¥4m

-CN¥678m

Sep 30 2020n/an/a

-CN¥922m

Jun 30 2020n/an/a

-CN¥1b

Mar 31 2020n/an/a

-CN¥1b

Dec 31 2019CN¥4mCN¥3m

-CN¥1b

Compensation vs Market: Dajun's total compensation ($USD653.18K) is below average for companies of similar size in the German market ($USD1.57M).

Compensation vs Earnings: Dajun's compensation has increased whilst the company is unprofitable.


CEO

Dajun Yang (61 yo)

16yrs

Tenure

CN¥4,781,000

Compensation

Dr. Dajun Yang, M.D., Ph D, co-founded Ascentage Pharma Group International in 2009 and serves as its Chairman from 2017 and has been its Director since November 17, 2017 and serves as its CEO since 2009....


Leadership Team

NamePositionTenureCompensationOwnership
Dajun Yang
Co-Founder16yrsCN¥4.78m7.39%
€ 125.0m
Shaomeng Wang
Co-Founderno dataCN¥1.17m4.1%
€ 69.4m
Ming Guo
Co-Founder15.7yrsno data4.27%
€ 72.2m
Jin Cao
Head of Finance4.1yrsno data0.0017%
€ 29.4k
Thomas Joseph Knapp
Senior VP & General Counsel5.8yrsno data0.10%
€ 1.8m
Yifan Zhai
Chief Medical Officer11.5yrsno data0.044%
€ 743.7k
Raymond Jeffrey Kmetz
Chief Business Officer5.9yrsno data0.058%
€ 985.2k
Chongdong Fu
Senior VP & Head of CMCno datano datano data
Cheung Ki Wong
Company Secretary6.5yrsno datano data

6.5yrs

Average Tenure

61yo

Average Age

Experienced Management: 36X's management team is seasoned and experienced (6.5 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dajun Yang
Co-Founder7.2yrsCN¥4.78m7.39%
€ 125.0m
Shaomeng Wang
Co-Founder7.2yrsCN¥1.17m4.1%
€ 69.4m
Allen S. Lichter
Chairman of the Clinical Advisory Board2yrsno datano data
Marina Bozilenko
Independent Non-Executive Directorless than a yearno datano data
Paul A. Bunn
Member of Clinical Advisory Boardno datano datano data
David Sidransky
Independent Non-Executive Director3.8yrsCN¥510.00k0.0026%
€ 43.6k
Jedd D. Wolchok
Member of Clinical Advisory Board3.8yrsno datano data
Arul M. Chinnaiyan
Member of Clinical Advisory Boardno datano datano data
Changqing Ye
Independent Non-Executive Director5.6yrsCN¥502.00k0.0022%
€ 36.7k
Dazhong Lu
Independent Non-Executive Director6.5yrsCN¥25.00k0%
€ 0
Wei Ren
Independent Non-Executive Director5.6yrsCN¥502.00k0.0022%
€ 36.7k
Asher A. Chanan-Khan
Member of Clinical Advisory Board2yrsno datano data

4.7yrs

Average Tenure

59yo

Average Age

Experienced Board: 36X's board of directors are considered experienced (4.7 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 08:42
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ascentage Pharma Group International is covered by 13 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yang HuangBofA Global Research
Jin ZhangChina International Capital Corporation Limited
Wangbin ZhouChina International Capital Corporation Limited